Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice
Diabetes2008Vol. 57(5), pp. 1331–1339
Citations Over TimeTop 10% of 2008 papers
Abstract
Treatment with a DPP-IV inhibitor can prolong islet graft retention in an animal model of type 1 diabetes.
Related Papers
- → Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes(2011)53 cited
- → Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)(2007)58 cited
- Clinical review of sitagliptin: a DPP-4 inhibitor.(2013)
- → Su1966 Sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, Can Be Effective Drug for Hepatic Iron Metabolism(2016)
- Dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin attenuates endothelial dysfunction(2011)